ArticleBlood transfusion = Trasfusione del sangue
FAR-BENE Study: pharmacoeconomics and well-being in hemophilia. Monitoring outcomes in light of pharmaceutical expenditure with focus on patients undergoing therapeutic switch.
Article in Blood transfusion = Trasfusione del sangue. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Towards a value-based approach in hemophilia: indications from the FAR-BENE study.Blood transfusion = Trasfusione del sangueArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
14 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundHemophilia, a rare bleeding disorder, raises significant pharmacoeconomic challenges, particularly with the emergence of innovative therapies. This study evaluates clinical and patient-reported outcomes and expenditures in hemophilia patients focusing on those who underwent therapeutic switches between 2017 and 2023. MATERIALS AND
methodsThis retrospective study included severe hemophilia patients. Expenditure was analyzed based on clotting factor consumption, while clinical well-being was assessed using ABR, NRS for pain, joint health scores (HJHS, HEAD-US) and trough plasma levels. A sub-analysis was conducted by applying different therapeutic groups. Statistical significance of differences between paired measures (pre [T0] vs post [T1]) was examined using the Wilcoxon Sum Rank test.
resultsSeventy patients were included. Total expenditure was € 12,947,580.44 in 2017 and € 12,967,576.92 in 2023. Among 45 patients who switched therapy, the median number of infusions/year significantly decreased from 156 to 91 (p<0.001), ABR from 1 to 0 (p<0.001) and NRS from 3,5 to 0 (p<0.001). Joint health did not show improvement with a slight but not statistically significant increase (HJHS from 10 to 15; HEAD-US from 7 to 8). Median trough increased from 3 IU/mL to 5 IU/mL (p=0.181). Patients were grouped for analysis based on homogeneous treatment regimens. DISCUSSION: This study is the first effort to conduct comprehensive analysis of the impact of therapeutic choices on well-being and cost of care in hemophilia Center. The study underscores the need for a value-based approach to hemophilia care, integrating expenditure and clinical outcomes. Adopting validated economic weight outcome in future pharmacoeconomic evaluations will be essential for decision making.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.